ProShares Nanotechnology ETF (TINY)
- Previous Close
46.09 - Open
45.60 - Bid 42.00 x 900
- Ask 49.53 x 1200
- Day's Range
44.65 - 45.19 - 52 Week Range
31.47 - 51.89 - Volume
927 - Avg. Volume
2,061 - Net Assets 4.97M
- NAV 46.18
- PE Ratio (TTM) --
- Yield 0.26%
- YTD Daily Total Return 10.44%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.58%
The index consists of companies focused on making or applying nanotechnology innovations that allow for improved products, processes, or techniques through control or measurement of material at nanoscale. The adviser seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction. The fund is non-diversified.
ProShares
Fund Family
Technology
Fund Category
4.97M
Net Assets
2021-10-26
Inception Date
Performance Overview: TINY
Trailing returns as of 4/18/2024. Category is Technology.
People Also Watch
Holdings: TINY
Top 10 Holdings (52.24% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: TINY
Daily – Vickers Top Buyers & Sellers for 04/19/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
ARWR: Lowering target price to $25.00
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $25.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetARWR: What does Argus have to say about ARWR?
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $31.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetARWR: Raising target price to $31.00
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $31.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice Target